BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
We met the management of Alkem Laboratories Ltd. to get an overview about the business outlook.
Approximately 71% of Alkem Labs’ FY22 revenue came from domestic formulations, 22% from the U.S. market and the balance from 40 other export markets. It is one of the prominent names in India in the acute therapy areas (85% of domestic branded sales) of anti-infective (rank one) gastro-intestinal (rank three), vitamins-minerals-nutrients (rank four) and pain (rank three).
The company has maintained its leading position in the anti-infective segment for more than 15 years. Overall, the company is the fifth largest pharmaceutical company in India in terms of market share and has one of the largest filed forces of over ~11,500 medical representatives in India.
Alkem Labs also has a growing presence in the chronic therapy areas of central nervous system, cardiovascular system, antidiabetes and dermatology.
Click on the attachment to read the full report:
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.